18-Fluorodeoxyglucose positron emission tomography/computed tomography for large vessel vasculitis in clinical practice

Kladoum Nassarmadji; Anthony Vanjak; Venceslas Bourdin; Karine Champion; Ruxandra Burlacu; Stéphane Mouly; Damien Sène; Cloé Comarmond

doi:10.3389/fmed.2023.1103752

18-Fluorodeoxyglucose positron emission tomography/computed tomography for large vessel vasculitis in clinical practice

Front Med (Lausanne). 2023 Jan 19:10:1103752. doi: 10.3389/fmed.2023.1103752. eCollection 2023.

Authors

Kladoum Nassarmadji¹, Anthony Vanjak¹, Venceslas Bourdin¹, Karine Champion¹, Ruxandra Burlacu¹, Stéphane Mouly¹, Damien Sène¹, Cloé Comarmond¹

Affiliation

¹ Department of Internal Medicine and Clinical Immunology, Lariboisière Hospital, Université Paris Cité, Paris, France.

Abstract

Diagnosis, prognostic assessment, and monitoring disease activity in patients with large vessel vasculitis (LVV) can be challenging. Early recognition of LVV and treatment adaptation is essential because vascular complications (aneurysm, dilatations, ischemic complications) or treatment related side effects can occur frequently in these patients. 18-fluorodeoxyglucose positron emission tomography/computed tomography (2-[18F]FDG-PET/CT) is increasingly used to diagnose, follow, and evaluate treatment response in LVV. In this review, we aimed to summarize the current evidence on the value of 2-[18F]FDG-PET/CT for diagnosis, follow, and treatment monitoring in LVV.

Keywords: 2-[18F]FDG-PET/CT; giant cell arteritis; large vessel arteritis; large vessel vasculitis; takayasu arteritis.

Publication types

Review